STOCK TITAN

Eyepoint Pharmac SEC Filings

EYPT Nasdaq

Welcome to our dedicated page for Eyepoint Pharmac SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

EyePoint Pharmaceuticals’ SEC filings are packed with dense ophthalmology data—think multi-phase trial outcomes, sustained-release chemistry, and milestone royalty clauses. Finding the R&D burn rate or the status of DURAVYU™ in a 300-page 10-K is challenging.

Stock Titan solves this problem. Our AI-powered summaries turn every EyePoint Pharmaceuticals SEC filing into plain English, so you can move from jargon to judgment in minutes. Whether you’re tracking an 8-K material event for trial readouts, skimming a quarterly earnings report 10-Q filing for cash runway, or reviewing proxy statement executive compensation, we deliver the context that matters.

You’ll find every form, updated in real time as they hit EDGAR:

  • EyePoint Pharmaceuticals insider trading Form 4 transactions with instant alerts
  • EyePoint Pharmaceuticals annual report 10-K simplified—AI highlights pivotal pipeline risks
  • EyePoint Pharmaceuticals Form 4 insider transactions real-time, revealing executive sentiment
  • EyePoint Pharmaceuticals earnings report filing analysis that pinpoints R&D spend trends
  • EyePoint Pharmaceuticals 8-K material events explained in clear language

Use our platform to:

  • Spot executive stock transactions before catalysts
  • Compare quarter-over-quarter clinical expense trajectories
  • Understand licensing revenue streams without combing footnotes

Stop wrestling with complex biotechnology disclosures. Start understanding EyePoint Pharmaceuticals SEC documents with AI—all in one place, always current.

Rhea-AI Summary

EyePoint Pharmaceuticals (EYPT) launched a primary offering of $150,000,000 of common stock via a prospectus supplement, with underwriters granted a 30‑day option to purchase up to an additional $22,500,000 at the public offering price, less underwriting discounts and commissions.

The company’s common stock trades on Nasdaq Global Market under “EYPT.” Estimated net proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes. EyePoint estimated approximately $200 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company states that existing cash plus expected net proceeds should fund operations into the fourth quarter of 2027.

Recent updates note DURAVYU’s Phase 3 program initiation planning in DME and ongoing Phase 3 trials in wet AMD. As context, shares outstanding were 68,889,649 as of June 30, 2025, plus 825,844 shares issued under an at‑the‑market program through October 6, 2025. A 60‑day lock‑up applies to the company and insiders, with specified exceptions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
prospectus
-
Rhea-AI Summary

EyePoint Pharmaceuticals (EYPT) filed an 8-K noting two updates. The company posted an investor presentation that includes estimated cash and investments as of September 30, 2025. These figures were calculated before review by the independent registered public accounting firm and are subject to change upon completion of the quarterly report for the period ended September 30, 2025.

EyePoint also announced details for its pivotal Phase 3 program evaluating DURAVYU (vorolanib intravitreal insert) for diabetic macular edema, with first patient dosing anticipated in Q1 2026. The press release and presentation were made available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
current report
-
Rhea-AI Summary

EyePoint Pharmaceuticals (EYPT) Chief Financial Officer George Elston reported transfers of company common stock on September 19, 2025. The filing shows 20,000 shares were disposed of from Mr. Elston's direct holdings and the same number were recorded as held indirectly in an irrevocable family trust for the benefit of his children, with JP Morgan Trust Company of Delaware as trustee. After the reported transactions, Mr. Elston's direct beneficial ownership is reported as 62,114 shares and the Family Trust holds 20,000 shares. The filing also notes 1,266 shares were acquired on July 31, 2025 under EyePoint’s 2019 Employee Stock Purchase Plan. The reporting attorney-in-fact signed the form on September 22, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 6,800,000 shares of EyePoint Pharmaceuticals common stock, representing 9.88% of the company based on 68,811,736 shares outstanding. The filing states the reporting persons hold shared voting and shared dispositive power over the shares and report no sole voting or dispositive power. Adage is identified as the investment manager of the entity that directly holds the shares. The reporting persons certify these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
current report
Rhea-AI Summary

Form 8-K/A overview: This amendment only fixes a broken hyperlink in the original 8-K filed 29 Jul 2025. The substance of the report is unchanged.

Material event (Item 8.01): EyePoint Pharmaceuticals (EYPT) has completed enrollment in its pivotal Phase 3 clinical trials of DURAVYU™ for wet age-related macular degeneration (wet AMD). Completion of enrollment marks the final operational step before data collection and analysis.

  • Press release detailing the milestone is furnished as Exhibit 99.1.
  • An updated investor presentation is furnished as Exhibit 99.2.

No financial results, guidance, or other transactions are disclosed. The filing signals continued pipeline progress but investors must await trial read-out for efficacy and safety outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Eyepoint Pharmac (EYPT)?

The current stock price of Eyepoint Pharmac (EYPT) is $11.73 as of October 15, 2025.

What is the market cap of Eyepoint Pharmac (EYPT)?

The market cap of Eyepoint Pharmac (EYPT) is approximately 907.1M.
Eyepoint Pharmac

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

907.08M
65.17M
3.51%
101.33%
12.26%
Biotechnology
Laboratory Analytical Instruments
Link
United States
WATERTOWN